store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Migalastat hydrochloride (GR181413A) 是一种可口服且具有有效和竞争性的 α-galactosidase A 抑制剂,可促进α-半乳糖苷酶A向溶酶体的运输,可用于研究法布里病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 298 | 现货 | ||
2 mg | ¥ 423 | 现货 | ||
5 mg | ¥ 689 | 现货 |
产品描述 | Migalastat hydrochloride (GR181413A) is an orally available, potent and competitive inhibitor of alpha-galactosidase A. It promotes the transport of alpha-galactosidase A to the lysosome and can be used in the study of Fabry disease. |
靶点活性 | α-GalA (human):0.04 μM (Ki), α-GalA (human):0.04 μM |
体外活性 | Migalastat hydrochloride (GR181413A) demonstrates IC50 and Ki values of 0.04 μM for human lysosomal alpha-Gal A[4]. |
体内活性 | Fabry disease is an X-linked recessive disorder caused by deficient activity of alpha-galactosidase A (α-Gal A)[2]. In transgenic mice expressing the mutant human α-Gal A (TgM), oral administration of Migalastat hydrochloride (3 mg/kg per day for 4 consecutive weeks) results in a dose- and time-dependent increase in α-Gal A activity in the heart, kidneys, spleen, and liver[2].After a 2-week pretreatment with Migalastat hydrochloride, the half-life for all major issues is less than 1 day[2]. Administration of Migalastat hydrochloride (100 mg/kg per day orally for 28 days) in transgenic mice leads to a reduction of 64%, 59%, and 81% in globotriaosylceramide (Gb3) levels in the kidneys, heart, and skin, respectively[3]. |
别名 | GR181413A hydrochloride, Migalastat HCl, GR181413A HCl |
分子量 | 199.63 |
分子式 | C6H14ClNO4 |
CAS No. | 75172-81-5 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (250.46 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 5.0093 mL | 25.0463 mL | 50.0927 mL | 125.2317 mL |
5 mM | 1.0019 mL | 5.0093 mL | 10.0185 mL | 25.0463 mL | |
10 mM | 0.5009 mL | 2.5046 mL | 5.0093 mL | 12.5232 mL | |
20 mM | 0.2505 mL | 1.2523 mL | 2.5046 mL | 6.2616 mL | |
50 mM | 0.1002 mL | 0.5009 mL | 1.0019 mL | 2.5046 mL | |
100 mM | 0.0501 mL | 0.2505 mL | 0.5009 mL | 1.2523 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Migalastat hydrochloride 75172-81-5 Others GR181413A hydrochloride Migalastat HCl GR181413A HCl GR181413A Inhibitor inhibitor inhibit